Skip to main content

Table 1 Characteristics of and medications for RA-ILD

From: Impact of radiological honeycombing in rheumatoid arthritis-associated interstitial lung disease

 Non-honeycomb groupHoneycomb groupP value
No. of patients2416 
Age, years, mean ± SD65.3 ± 11.667.9 ± 7.40.443
Male, N (%)8 (33%)8 (50%)0.339
Current or ex-smoker, N (%)11 (46%)9 (56%)0.748
Initial CT pattern, N (%)  0.491
Probable UIP9 (38%)5 (31%) 
Indeterminate; mixed NSIP/UIP9 (38%)9 (56%) 
NSIP6 (25%)2 (13%) 
CPFE, N (%)7 (29%)2 (13%)0.272
Acute exacerbation of ILD during follow-up, N (%)4 (17%)3 (19%)> 0.999
KL-6, U/mL, mean ± SD804.7 ± 525.91150.1 ± 791.40.114
SP-D, ng/mL, mean ± SD144.3 ± 121.0172.2 ± 136.40.610
%FVC, mean ± SD84.5 ± 20.282.8 ± 14.20.812
FEV1/FVC ratio, % mean ± SD81.5 ± 7.886.6 ± 6.80.122
%DLCO, mean ± SD67.5 ± 14.862.2 ± 12.50.420
CPI, mean ± SD32.4 ± 12.141.0 ± 11.30.138
Median follow-up period of CT scans, years (range)4.0 (1.1–10.3)5.2 (2.9–8.7)0.194
Median observation follow-up, years (range)4.7 (1.4–12.7)6.2 (2.8–10.1)0.269
Deaths (during follow-up), N6 (25%)7 (44%)0.305
Cause of death, N  0.643
Chronic respiratory failure12 
Acute exacerbation31 
Malignancy11 
Others13 
Medications used during follow-up, N   
Corticosteroid9110.105
Methotrexate930.297
Iguratimod300.262
Calcineurin inhibitor970.750
Biologics520.681
Pirfenidone or nintedanib010.400
  1. RA rheumatoid arthritis; ILD interstitial lung disease; SD standard deviation; CTD connective tissue disease; CT computed tomography; UIP usual interstitial pneumonia; NSIP nonspecific interstitial pneumonia; CPFE combined pulmonary fibrosis with emphysema; KL-6 Krebs von den Lungen-6; SP-D surfactant protein-D; FVC forced vital capacity; FEV1 forced expiratory volume in 1 s; DLCO diffusing capacity of the lung for carbon monoxide; CPI composite physiological index
\